Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 2/2013

01-04-2013 | Pathogenesis of Hypertension (R Agarwal, Section Editor)

Sympathetic Hyperactivity in Chronic Kidney Disease: Pathophysiology and (New) Treatment Options

Authors: Eva E. Vink, Rosa L. de Jager, Peter J. Blankestijn

Published in: Current Hypertension Reports | Issue 2/2013

Login to get access

Abstract

Abundant evidence shows that chronic kidney disease (CKD) is a disease state characterized by increased sympathetic activation. Kidney injury (ischemia) plays a central role in this pathogenesis. Sympathetic excitation is associated with an increased risk of cardiovascular morbidity and mortality. Several pharmacologic strategies are developed to decrease sympathetic activity. However, these medications have limitations. Percutaneous catheter-based renal denervation has the potential to become a new treatment option for CKD. This current report focuses on the effects of sympathetic hyperactivity in CKD, and gives an overview in experimental as well as clinical evidence for a central role of the kidneys in the pathophysiology of sympathetic hyperactivity. Moreover, the effect of pharmacologic treatment and the potential beneficial effect of renal denervation will be discussed.
Literature
1.
Matsushita K, van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073–81.PubMedCrossRef
2.
Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:1296–305.PubMedCrossRef
3.
Mahmoodi BK, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet. 2012;380:1649–61.PubMedCrossRef
4.
Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002;105:1354–9.PubMedCrossRef
5.
Penne EL, Neumann J, Klein IH, et al. Sympathetic hyperactivity and clinical outcome in chronic kidney disease patients during standard treatment. J Nephrol. 2009;22:208–15.PubMed
6.
Esler M, Jennings G, Lambert G, et al. Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. Physiol Rev. 1990;70:963–85.PubMed
7.
Malpas SC. Sympathetic nervous system overactivity and its role in the development of cardiovascular disease. Physiol Rev. 2010;90:513–57.PubMedCrossRef
8.
Fagius J, Wallin BG. Long-term variability and reproducibility of resting human muscle nerve sympathetic activity at rest, as reassessed after a decade. Clin Auton Res. 1993;3:201–5.PubMedCrossRef
9.
Siddiqi L, Prakken NH, Velthuis BK, et al. Sympathetic activity in chronic kidney disease patients is related to left ventricular mass despite antihypertensive treatment. Nephrol Dial Transplant. 2010;25:3272–7.PubMedCrossRef
10.
Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant 2011;11:2176–80.
11.
Ligtenberg G, Blankestijn PJ, Oey PL, et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med. 1999;340:1321–8.PubMedCrossRef
12.
Klein IHHT, Ligtenberg G, Oey PL, et al. Sympathetic activity is increased in polycystic kidney disaese and is associated with hypertension. J Am Soc Nephrol. 2001;12:2427–33.PubMed
13.
Klein IH, Ligtenberg G, Oey PL, et al. Enalapril and losartan reduce sympathetic hyperactivity in patients with chronic renal failure. J Am Soc Nephrol. 2003;14:425–30.PubMedCrossRef
14.
Neumann J, Ligtenberg G, Oey L, et al. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol. 2004;15:2902–7.PubMedCrossRef
15.
Wallin BG, Esler M, Dorward P, et al. Simultaneous measurements of cardiac noradrenaline spillover and sympathetic outflow to skeletal muscle in humans. J Physiol. 1992;453:45–58.PubMed
16.
Wallin BG, Thompson JM, Jennings GL, Esler MD. Renal noradrenaline spillover correlates with muscle sympathetic activity in humans. J Physiol. 1996;491(Pt 3):881–7.PubMed
17.
Reid IA. Interactions between ANG II, sympathetic nervous system, and baroreceptor reflexes in regulation of blood pressure. Am J Physiol. 1992;262:E763–78.PubMed
18.
Ye S, Gamburd M, Mozayeni P, et al. A limited renal injury may cause a permanent form of neurogenic hypertension. Am J Hypertens. 1998;11:723–8.PubMedCrossRef
19.
Campese VM, Kogosov E. Renal afferent denervation prevents hypertension in rats with chronic renal failure. Hypertension. 1995;25:878–82.PubMedCrossRef
20.
Campese VM, Kogosov E, Koss M. Renal afferent denervation prevents the progression of renal disease in the renal ablation model of chronic renal failure in the rat. Am J Kidney Dis. 1995;26:861–5.PubMedCrossRef
21.
Bigazzi R, Kogosov E, Campese VM. Altered norepinephrine turnover in the brain of rats with chronic renal failure. J Am Soc Nephrol. 1994;4:1901–7.PubMed
22.
Katholi RE, Whitlow PL, Hageman GR, Woods WT. Intrarenal adenosine produces hypertension by activating the sympathetic nervous system via the renal nerves in the dog. J Hypertens. 1984;2:349–59.PubMed
23.
Koomans HA, Blankestijn PJ, Joles JA. Sympathetic hyperactivity in chronic renal failure: a wake-up call. J Am Soc Nephrol. 2004;15:524–37.PubMedCrossRef
24.
Converse Jr RL, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327:1912–8.PubMedCrossRef
25.
Hausberg M, Kosch M, Harmelink P, et al. Sympathetic nerve activity in end-stage renal disease. Circulation. 2002;106:1974–9.PubMedCrossRef
26.
Klein IH, Ligtenberg G, Neumann J, et al. Sympathetic nerve activity is inappropriately increased in chronic renal disease. J Am Soc Nephrol. 2003;14:3239–44.PubMedCrossRef
27.
Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure. Hypertension. 2011;57:846–51.PubMedCrossRef
28.
Grassi G, Cattaneo BM, Seravalle G, et al. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension. 1998;31:68–72.PubMedCrossRef
29.
Gabow PA, Chapman AB, Johnson AM, et al. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int. 1990;38:1177–80.PubMedCrossRef
30.
Miyajima E, Yamada Y, Yoshida Y, et al. Muscle sympathetic nerve activity in renovascular hypertension and primary aldosteronism. Hypertension. 1991;17:1057–62.PubMedCrossRef
31.
Amann K, Rump LC, Simonaviciene A, et al. Effects of low dose sympathetic inhibition on glomerulosclerosis and albuminuria in subtotally nephrectomized rats. J Am Soc Nephrol. 2000;11:1469–78.PubMed
32.
Veelken R, Vogel EM, Hilgers K, et al. Autonomic renal denervation ameliorates experimental glomerulonephritis. J Am Soc Nephrol. 2008;19:1371–8.PubMedCrossRef
33.
Takamitsu Y, Nakanishi T, Nishihara F, et al. A nitric oxide-generating beta-blocking agent prevents renal injury in the rat remnant kidney model. Comparative study of two beta-blocking drugs, nipradilol and propranolol. Nephron Physiol. 2003;93:42–50.CrossRef
34.
Brooks DP, Short BG, Cyronak MJ, et al. Comparison between carvedilol and captopril in rats with partial ablation-induced chronic renal failure. Br J Pharmacol. 1993;109:581–6.PubMedCrossRef
35.
Nagasu H, Satoh M, Kuwabara A, et al. Renal denervation reduces glomerular injury by suppressing NAD(P)H oxidase activity in Dahl salt-sensitive rats. Nephrol Dial Transplant. 2010;25:2889–98.PubMedCrossRef
36.
Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol. 2004;24:354–65.PubMedCrossRef
37.
Vonend O, Marsalek P, Russ H, et al. Moxonidine treatment of hypertensive patients with advanced renal failure. J Hypertens. 2003;21:1709–17.PubMedCrossRef
38.
Wallin BG, Sundlof G, Stromgren E, Aberg H. Sympathetic outflow to muscles during treatment of hypertension with metoprolol. Hypertension. 1984;6:557–62.PubMedCrossRef
39.
Burns J, Mary DA, Mackintosh AF, et al. Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive. Hypertension. 2004;44:454–8.PubMedCrossRef
40.
Bakris GL, Hart P, Ritz E. Beta blockers in the management of chronic kidney disease. Kidney Int. 2006;70:1905–13.PubMed
41.
Grassi G, Seravalle G, Turri C, et al. Short-versus long-term effects of different dihydropyridines on sympathetic and baroreflex function in hypertension. Hypertension. 2003;41:558–62.PubMedCrossRef
42.
Siddiqi L, Joles JA, Oey PL, Blankestijn PJ. Atorvastatin reduces sympathetic activity in patients with chronic kidney disease. J Hypertens. 2011;29:2176–80.PubMedCrossRef
43.
Menon DV, Arbique D, Wang Z, et al. Differential effects of chlorthalidone versus spironolactone on muscle sympathetic nerve activity in hypertensive patients. J Clin Endocrinol Metab. 2009;94:1361–6.PubMedCrossRef
44.
Raheja P, Price A, Wang Z, et al. Spironolactone prevents chlorthalidone-induced sympathetic activation and insulin resistance in hypertensive patients. Hypertension. 2012;60:319–25.PubMedCrossRef
45.
Peet MM. Hypertension and its surgical treatment by bilateral supradiaphragmatic splanchnicectomy. Am J Surg. 1948;75:48–68.PubMedCrossRef
46.
Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–81.PubMedCrossRef
47.
• Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet. 2010;376:1903–9. The first randomized controlled trial investigating safety and efficacy of renal denervation as treatment of resistant hypertension.PubMedCrossRef
48.
Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57:911–7.CrossRef
49.
• Schlaich MP, Sobotka PA, Krum H, et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932–4. The first report investigating the effect of renal denervation on MSNA.PubMedCrossRef
50.
• Brinkmann J, Heusser K, Schmidt BM et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients: prospective case series. Hypertension 2012;11:1485–90. One of the first reports investigating the effect of renal denervation on MSNA.
51.
• Hering D, Lambert EA, Marusic P et al. Substantial reduction in single sympathetic nerve firing after renal denervation in patients with resistant hypertension. Hypertension 2012;2:457–64. One of the first reports investigating the effect of renal denervation on MSNA.
52.
Vink EE, Blankestijn PJ. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult-to-control hypertensive patients. Hypertension 2012;61:e8.
53.
• Brandt MC, Mahfoud F, Reda S, et al. Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension. J Am Coll Cardiol. 2012;59:901–9. The first randomized controlled trial investigating the effect of renal denervation on left ventricular hypertrophy in patients with hypertension.PubMedCrossRef
54.
Mahfoud F, Schlaich M, Kindermann I, et al. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: a pilot study. Circulation. 2011;123:1940–6.PubMedCrossRef
55.
• Hering D, Mahfoud F, Walton AS et al. Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012. The first pilot study investigating safety and efficacy of renal denervation in CKD.
56.
Di Danielle DN, De FM, Violo L, et al. Renal sympathetic nerve ablation for the treatment of difficult-to-control or refractory hypertension in a haemodialysis patient. Nephrol Dial Transplant. 2012;27:1689–90.CrossRef
57.
Ott C, Schmid A, Ditting T, et al. Renal denervation in a hypertensive patient with end-stage renal disease and small arteries: a direction for future research. J Clin Hypertens. 2012;14:799–801.CrossRef
Metadata
Title
Sympathetic Hyperactivity in Chronic Kidney Disease: Pathophysiology and (New) Treatment Options
Authors
Eva E. Vink
Rosa L. de Jager
Peter J. Blankestijn
Publication date
01-04-2013
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 2/2013
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-013-0328-5

Other articles of this Issue 2/2013

Current Hypertension Reports 2/2013 Go to the issue

Pathogenesis of Hypertension (R Agarwal, Section Editor)

Does Kidney Disease Cause Hypertension?

Hot Topic

Urinary Markers of Intrarenal Renin-Angiotensin System Activity In Vivo

Pathogenesis of Hypertension (R Agarwal, Section Editor)

Aldosterone and the Risk of Hypertension

Pathogenesis of Hypertension (R Agarwal, Section Editor)

Sodium and Potassium and the Pathogenesis of Hypertension

Pathogenesis of Hypertension (R Agarwal, Section Editor)

Preeclampsia and the Future Risk of Hypertension: The Pregnant Evidence

Pathogenesis of Hypertension (R Agarwal, Section Editor)

A Consideration of Genetic Mechanisms Behind the Development of Hypertension in Blacks
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits